Similarly, in our melanoma models, exogenously administered IL-33 activated mDCs in the TME, promoting cross-presentation of tumor antigen in a ST2/MyD88/STAT1-dependent fashion and restoring a competent anti-tumor T cell activity [40]. The gene discussed is MYD88; the disease is neoplasm.